Boryung to Spin Off Prescription Drug Sales Unit into Subsidiary

Boryung will spin off its prescription drug sales unit into a new unlisted subsidiary. This move allows Boryung to focus on its core business while potentially unlocking value from the separated entity. The exact date or additional financial details regarding the spin-off have not been disclosed. This decision may impact Boryung's operational strategy and investor perception moving forward, making it important for stakeholders to monitor the development closely.